Moderna Today Moderna -5.20 (-3.58%) ▼ Price Target $129.02 Biotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments. The company continues expanding its treatments for various diseases and illnesses, including cardiovascular disease, cancer, and other rare diseases. Moderna has been working on personalized cancer vaccines that will enable a cancer p ...

The company's post-pandemic prospects are getting brighter. Moderna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dropped off a cliff. However, the biotech has been looking to move beyond this therapeutic area. It recently earned approval for a vaccine for the respiratory syncytial virus (RSV). Even more rec ...

Moderna(MRNA) announced positive results from the pivotal phase III NextCOVE study evaluating mRNA1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older. Image Source: Zacks Investment Research The study achieved its primary efficacy endpoint, demonstrating the non-inferior vaccine efficacy of mRNA1283 against COVID-19 when compared to mRNA-1273.222, Moderna's previously approved bivalent Omicron BA.4/BA.5-targeting COVID-19 vaccine. A higher efficacy was also ...

Moderna intends to engage with regulatory authorities for regulatory submissions. Management intends to market mRNA-1083 by 2025. Year to date, Moderna's shares have surged 49.4% against the industry's 5.9% fall. Image Source: Zacks Investment Research Last year, Moderna provided a positive interim update from a phase III immunogenicity study (P303) on mRNA-1010 in older adults. Data from the study showed that mRNA-1010 elicited higher immune responses across all four A and B strains of influenza than GSK's ...

On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating. FDA settled on targeting JN.1 — the variant responsible for most Covid cases of early this year. A vaccine targeting JN. 1 should offer broader protection against its offshoots KP.2, KP.3 and others that may pop ...

Shares of the biotechnology company have appreciated by 28.73% over the course of the past month, outperforming the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.46 per share and revenue of $4.05 billion. These totals would mark changes of +39.5% and -40.83%, respectively, from last year. Our research reveals that these estimate alterations are directly linked with the stock price perform ...

Moderna, Inc. (NASDAQ:MRNA) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 1:20 PM ET Company Participants Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good afternoon, everyone. Thank you so much for joining us. Really pleased to have Stephen Hoge, President of Moderna with us this morning. Stephen Hoge Thanks for having us. Question-and-Answer Session Q - Salveen Richter After having just announced some news today on the ...

Moderna, Inc. (MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic. The regulatory filing is based on guidance from the FDA last week, whereby the regulatory body advised eminent vaccine manufacturers like Moderna, Novavax (NVAX) and Pfizer (PFE) to update their respective COVID-19 vaccines to a monovalent (single strain) JN.1 compositio ...

Moderna has announced promising data on a combination COVID-flu vaccine. This trial tested the combination vaccine in two groups of roughly 4,000 adults, one aged 65 and older and other between 50 and 64 years, and used blood tests to assess the strength of immune response generated by two different vaccines for the viruses administered at the same time. Moderna has not published data from the trial or opened it up to external scrutiny but said it plans to present data at an upcoming medical conference and ...

The biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rival vaccine makers Pfizer and Novavax. Bancel added that combination shots could reduce the burden of respiratory viruses on pharmacists and the broader U.S. health-care system, which has been grappling with a labor shortage that has many workers stretched thin. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's current ...